The Influence of Diabetes Mellitus Duration and Type of Therapy on Cognitive Decline

被引：0
作者：
Khairullin I. [1 ,3 ,4 ]
Abakumova A. [1 ]
Esin R. [1 ,2 ,3 ,4 ]
Esin O. [1 ,3 ,4 ]
机构：
[1] University Clinic, Kazan Federal University, 1a Chekov str, Kazan
[2] Department of Neurology and Manual Therapy, Kazan State Medical Academy, 11 Mushtari str, Kazan
[3] Department of Russian Language and Applied Linguistics, Kazan Federal University, 2 Tatarstan str, Kazan
[4] Laboratory of Clinical Linguistics, Kazan Federal University, 2 Tatarstan str, Kazan
来源：
BioNanoScience | 2017年 / 7卷 / 1期
关键词：
Cognitive decline; Dementia; Diabetes mellitus type 2; Diabetic encephalopathy; Insulin resistance;
D O I：
10.1007/s12668-016-0345-3
中图分类号：
学科分类号：
摘要：
We studied 120 patients with compensated diabetes mellitus type 2 (DM-2). The inclusion criterion was the absence of memory loss complaints from the patient and/or his/her relatives. The exclusion criteria were diabetes decompensation, myocardial infarction and/or stroke in anamnesis, glomerular filtration rate below 60 ml/min, the presence of proliferative retinopathy, and/or other endocrine diseases. To diagnose the cognitive decline (CD) we used Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA test), Trail Making Test (parts A and B). 77.5 % patients with type 2 diabetes out of 120 had moderate CD; 5 % had a significant CD (dementia). The control group consisted of 50 patients with arterial hypertension, which was comparable with the DM-2 group. In assessing the correlations, we found that the CD in DM-2 group is independent of disease duration and the type of diabetic therapy. We discovered a positive correlation between the age of patients and the speed of cognitive decline. Comparison of patients in DM-2 group with the control group showed that results in patients with hypertension (MMSE, MoCA test) were significantly higher (p < 0.01), and the test time of TMT part A and part B was significantly lower (p < 0.01) than that in patients with DM-2. The authors believe that the CD in DM-2 has different pathogenic mechanisms than other complications of type 2 diabetes mellitus, in particular, the insulin resistance of brain tissue. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：251 / 253
页数：2
相关论文
共 11 条
  • [1] De Jong R.N., The nervous system complications of diabetes mellitus, with special reference to cerebrovascular changes, Journal of Nervous Mental Disease, 3, 49, pp. 181-206, (1950)
  • [2] Vijayakumar T.M., Mechanism linking cognitive impairment and diabetes mellitus, European Journal of Applied Sciences, 4, 1, pp. 01-05, (2012)
  • [3] Khairullin I., Esin R., Pozdnyak A., The potential for correcting cognitive decline in patients with type 2 diabetes mellitus, Neuroscience Behavioral Physics, 46, 3, pp. 360-364, (2016)
  • [4] Nooyens A., Baan C., Spijkerman A., Verschuren W., Type 2 diabetes and cognitive decline in middle-aged men and women: the doetinchem cohort study, Diabetes Care, 33, 9, pp. 1964-1969, (2010)
  • [5] Kawamura T., Umemura T., Hotta N., Cognitive impairment in diabetic patients: can diabetic control prevent cognitive decline?, Journal Of Diabetes Investigation, 3, 5, pp. 413-423, (2012)
  • [6] Folstein M., Folstein S., Mchugh P., Mini-mental state: a practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatry Research, 12, pp. 189-198, (1975)
  • [7] (2010)
  • [8] Corrigan J., Hinkeldey M., Relationships between parts A and B of the trail making test, Journal of Clinical Psychology, 43, 4, pp. 402-409, (1987)
  • [9] Blazquez E., Velazquez E., Hurtado-Carneiro V., Ruiz-Albusac J., Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 Diabetes and Alzheimer’s disease, Frontiers in Endocrinology, (2014)
  • [10] Vijayakumar T.M., Sirisha G.B.N., Begam F., Dhanaraju M.D., Mechanism linking cognitive impairment and diabetes mellitus, European Journal of Applied Sciences, 4, 1, pp. 1-5, (2012)
12